Roche Diagnostics is the market leader in the in vitro diagnostics business and provides the largest number of test results, empowering physicians and patients to make informed health decisions.
Roche was one of the first companies to recognise the importance of external innovation. Diagnostics has been partnering for more than 20 years with companies and research institutes worldwide. Since then, we have maintained a model that values external innovation as highly as our own internal development and established collaborations as the cornerstone of our R&D strategy.
acquisitions since 2014
licencing and R&D agreements since 2014
Roche is the in vitro diagnostics market leader
in diagnostic sales achieved in 2019
tests conducted with Roche instruments in 2019
Diagnostics Partnering offers speed, flexibility and accessibility to our partners. We have offices in Santa Clara, Tucson, Pleasanton, Boston, Basel (HQ), Rotkreuz, Penzberg and Shanghai.
The Roche partnering process can be encapsulated in four steps.
Defining our search
At each step we can modify and tailor the relationship to the specific needs of each potential partner and depending on what is best for the asset. We find that this flexible approach is welcomed by our partners, and in our experience delivers the best results.
We identify the “Wants” of Roche Diagnostics in regular reviews with our Business and R&D functions. The “Wants” cover short-term as well as mid- and long-term goals. We work closely with the potential partner to answer questions that focus on unmet medical needs, integration into existing platforms and assay menus, reimbursement, connectivity with our platforms, data sourcing, decision support and future trends with disruptive potential.
In order to be able to answer those questions during evaluation, we need to rely on data provided by the partner for each potential opportunity.
Once a new opportunity is identified, dedicated negotiation teams will work alongside our partners to complete the deal. We do not have any preconceived notions on the type of deals we should make. Our business development organisation can manage each transaction type and can easily change the structure to suit the needs of each of the opportunities and partners. We are flexible and consider a variety of deal types that range from licensing and acquisitions, to option deals and collaboration/partnering agreements, depending on what is best for all parties. If the opportunity permits, we work collaboratively with Pharma Partnering and Genentech Partnering to ensure the best outcome for the patients and the partners. Following execution of co-development projects we will have alliance management teams which work closely with the partner to set the development up for success.
If you have an opportunity for collaboration or an interesting technology, or if you have an asset in one of our areas of interest, we would like to hear from you.